Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
Herzog TJ, Monk BJ, Rose PG, Braly P, Hines JF, Bell MC, Wenham RM, Secord AA, Roman LD, Einstein MH, Drake RD, Childs BH. Herzog TJ, et al. Among authors: wenham rm. Gynecol Oncol. 2014 Mar;132(3):517-25. doi: 10.1016/j.ygyno.2014.01.035. Epub 2014 Jan 27. Gynecol Oncol. 2014. PMID: 24476788 Free PMC article. Clinical Trial.
The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.
Bou Zgheib N, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM. Bou Zgheib N, et al. Among authors: wenham rm. Int J Oncol. 2012 Jul;41(1):179-88. doi: 10.3892/ijo.2012.1451. Epub 2012 Apr 26. Int J Oncol. 2012. PMID: 22552627 Free PMC article.
A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
Secord AA, Teoh DK, Barry WT, Yu M, Broadwater G, Havrilesky LJ, Lee PS, Berchuck A, Lancaster J, Wenham RM. Secord AA, et al. Among authors: wenham rm. Clin Cancer Res. 2012 Oct 1;18(19):5489-98. doi: 10.1158/1078-0432.CCR-12-0507. Epub 2012 Jul 26. Clin Cancer Res. 2012. PMID: 22837181 Free PMC article. Clinical Trial.
A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM. Marchion DC, et al. Among authors: wenham rm. Oncol Rep. 2013 May;29(5):2011-8. doi: 10.3892/or.2013.2329. Epub 2013 Mar 5. Oncol Rep. 2013. PMID: 23467907 Free PMC article.
124 results